Your browser doesn't support javascript.
loading
Galectin-1-driven T cell exclusion in the tumor endothelium promotes immunotherapy resistance.
Nambiar, Dhanya K; Aguilera, Todd; Cao, Hongbin; Kwok, Shirley; Kong, Christina; Bloomstein, Joshua; Wang, Zemin; Rangan, Vangipuram S; Jiang, Dadi; von Eyben, Rie; Liang, Rachel; Agarwal, Sonya; Colevas, A Dimitrios; Korman, Alan; Allen, Clint T; Uppaluri, Ravindra; Koong, Albert C; Giaccia, Amato; Le, Quynh Thu.
Affiliation
  • Nambiar DK; Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California, USA.
  • Aguilera T; Department of Radiation Oncology, University of Texas Southwestern, Dallas, Texas, USA.
  • Cao H; Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California, USA.
  • Kwok S; Department of Pathology, Stanford University School of Medicine, Stanford, California, USA.
  • Kong C; Department of Pathology, Stanford University School of Medicine, Stanford, California, USA.
  • Bloomstein J; Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California, USA.
  • Wang Z; Biologics Discovery California, Bristol-Myers Squibb, Redwood City, California, USA.
  • Rangan VS; Biologics Discovery California, Bristol-Myers Squibb, Redwood City, California, USA.
  • Jiang D; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • von Eyben R; Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California, USA.
  • Liang R; Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California, USA.
  • Agarwal S; Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California, USA.
  • Colevas AD; Department of Medicine, Stanford University School of Medicine, Stanford, California, USA.
  • Korman A; Biologics Discovery California, Bristol-Myers Squibb, Redwood City, California, USA.
  • Allen CT; Translational Tumor Immunology Program, National Institute on Deafness and Other Communication Disorders (NIDCD), Bethesda, Maryland, USA.
  • Uppaluri R; Department of Surgery - Otolaryngology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Koong AC; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Giaccia A; Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California, USA.
  • Le QT; Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California, USA.
J Clin Invest ; 129(12): 5553-5567, 2019 12 02.
Article in En | MEDLINE | ID: mdl-31710313
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: T-Lymphocytes / Galectin 1 / Endothelium / B7-H1 Antigen / Programmed Cell Death 1 Receptor / Head and Neck Neoplasms Type of study: Prognostic_studies Limits: Adult / Aged / Aged80 / Animals / Female / Humans / Male / Middle aged Language: En Journal: J Clin Invest Year: 2019 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: T-Lymphocytes / Galectin 1 / Endothelium / B7-H1 Antigen / Programmed Cell Death 1 Receptor / Head and Neck Neoplasms Type of study: Prognostic_studies Limits: Adult / Aged / Aged80 / Animals / Female / Humans / Male / Middle aged Language: En Journal: J Clin Invest Year: 2019 Document type: Article Affiliation country: Country of publication: